Dr. Brian Rood, MD
Claim this profileClinical Trials Brian Rood, MD is currently running
More about Brian Rood, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Brian Rood, MD has experience with
- Multi-tumor Antigen Specific Cytotoxic T Lymphocytes (TSA-T)
Breakdown of trials Brian Rood, MD has run
Medulloepithelioma
Rhabdoid Tumor
Pineal Tumors
Pinealoblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian Rood, MD specialize in?
Brian Rood, MD focuses on Medulloepithelioma and Solid Tumors. In particular, much of their work with Medulloepithelioma has involved treating patients, or patients who are undergoing treatment.
Is Brian Rood, MD currently recruiting for clinical trials?
Yes, Brian Rood, MD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Brian Rood, MD has studied deeply?
Yes, Brian Rood, MD has studied treatments such as Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T).
What is the best way to schedule an appointment with Brian Rood, MD?
Apply for one of the trials that Brian Rood, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.